10-K: Impact BioMedical Inc. Reports Full Year 2024 Results, Highlights IPO and IP Expansion

Impact BioMedical Inc.'s 2024 annual report highlights its IPO completion, intellectual property expansion, and ongoing development of its technology portfolio despite incurring a net loss.

Summary

• Impact BioMedical Inc. (IBO) released its annual report for the fiscal year ended December 31, 2024.
• The company focuses on discovering, confirming, and patenting technologies for human healthcare and wellness.
• IBO completed its Initial Public Offering (IPO) in September 2024, raising $3,726,000 net of issuance costs.
• The company successfully restructured its long-term debt, improving financial flexibility.
• Three new patent platforms were established in 2024, adding to the existing IP portfolio.
• The Equivir platform, licensed to ProPhase Labs, completed its first human study with results expected in mid-2025.
• The company reported a net loss of $24,770,000 for 2024, compared to a net loss of $4,407,000 in 2023.
• Operating expenses increased significantly due to impairment of goodwill and increased sales and marketing costs.
• The company impaired goodwill by $25,093,000 during the fourth quarter of 2024.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern without additional funding or revenue generation.
• The company is focusing on monetization of its intellectual properties and tightly controlling operating costs.
• The company identified material weaknesses in its internal control over financial reporting.
• The company is taking steps to remediate these weaknesses, including hiring additional accounting personnel and centralizing accounting functions.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company highlights positive developments such as the IPO and IP expansion, the significant net loss, goodwill impairment, and going concern uncertainty weigh heavily on the overall outlook.

Positives

• The company completed its IPO, providing resources for research and development.
• Long-term debt was restructured, improving financial flexibility.
• The IP portfolio was expanded with three new patent platforms.
• The Equivir platform completed its first human study, showing potential for commercialization.
• The company is actively seeking partners for further development and commercialization of its technologies.
• The company is taking steps to remediate material weaknesses in internal controls.

Negatives

• The company reported a significant net loss of $24,770,000 for 2024.
• Operating expenses increased substantially due to impairment of goodwill.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company identified material weaknesses in its internal control over financial reporting.
• The company has not generated revenue for the years ended December 31, 2024 or 2023.

Risks

• The company may not have adequate funds to implement its business plan.
• The company's ability to resell and/or license its products will depend upon successful clinical trials.
• The company faces significant competition from other biopharmaceutical and consumer product companies.
• The company is dependent on its collaborative agreements for the development of products and business development, which exposes it to the risk of reliance on the viability of third parties.
• The company is increasingly dependent on information technology systems to operate its business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.
• If the company is unable to obtain U.S. and/or foreign regulatory approval, it will be unable to resell or license its drug candidates.
• The company relies on various intellectual property rights, including patents and licenses, in order to operate its business.
• The market price of the company's common stock may be highly volatile, and you could lose all or part of your investment.

Future Outlook

The company's management intends to take additional actions necessary to continue as a going concern, including monetization of its intellectual properties and tightly controlling operating costs.

Management Comments

• As a relatively new public entity, Impact BioMedical (IBO) has already demonstrated an ability to establish an experienced leadership team, attract investor confidence, build a robust intellectual property(IP) portfolio, and create partnerships for development, registration, and commercialization.
• IBO is built on a foundation of cutting-edge technologies, strong IP, and partnerships to improve human health and wellness.
• 2024 delivered an improved financial position, platform and regional expansion of IP estate, completion of the first human study with IBO technology (Equivir) with potential for near-term revenue generation, and a dedicated leadership team.

Industry Context

Impact BioMedical operates in the competitive biopharmaceutical and consumer healthcare industries, facing competition from major pharmaceutical companies, academic institutions, and research institutions. The company's success depends on its ability to innovate, secure intellectual property protection, obtain regulatory approvals, and establish strategic collaborations.

Comparison to Industry Standards

• It is difficult to compare Impact BioMedical's results directly to industry standards due to its early stage of development and unique business model.
• Many comparable companies are larger, more established pharmaceutical or biotechnology firms with significant revenue streams.
• The company's focus on licensing and partnerships distinguishes it from companies that primarily rely on direct sales.
• ProPhase Labs (PRPH), a partner of Impact BioMedical, is a publicly traded company in the diagnostics and genomics testing space, but its overall business model differs significantly.
• The company's success will depend on its ability to execute its business plan and generate revenue from its technology portfolio.

Related Party Transactions

• The company has a Revolving Promissory Note with DSS, a related party, with an outstanding balance of $8,878,000 as of December 31, 2024.
• The company incurred $357,000 in general and administrative costs from DSS, a related party, during 2024.
• The company has a Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC, a related party.

Stakeholder Impact

• Shareholders: The significant net loss and going concern uncertainty could negatively impact shareholder value.
• Employees: Cost-cutting measures and potential financial instability could affect employee job security.
• Customers: The company's ability to develop and commercialize its technologies could be impacted by its financial challenges.
• Creditors: The company's ability to repay its debts is uncertain given its financial condition.

Next Steps

• The company intends to monetize its intellectual properties.
• The company intends to tightly control operating costs.
• The company will document and test the remediations put in place to strengthen internal controls during the 2025 fiscal year.

Key Dates

Keywords

intellectual property, biomedical, biopharmaceutical, Equivir, Laetose, Linebacker, patents, IPO, clinical trials, revenue, debt, licensing, research and development